Filing Flows

Filing Flows › Recursion Pharmaceuticals (RXRX) › Next earnings date

Recursion Pharmaceuticals (RXRX) earnings: beat the estimate

Recursion Pharmaceuticals (RXRX) reported on Nov 2, 2026 and beat the EPS estimate: −$0.22 against −$0.23 (+3.9%). Revenue was $18.6M for Q3 2026, +258% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+3.9% vs estimate
Beat rate80%

The last report

Recursion Pharmaceuticals reported revenue of $18.6M for the third quarter 2026 (+258% Y/Y), net loss $119M: Operating revenue $18.1M, Grant revenue $497K. How it makes money → · Every quarter →

Recursion Pharmaceuticals: EPS against the estimate, last 5 reportsRecursion Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$0.38−$0.36Nov 25−$0.32−$0.21Feb 26−$0.26−$0.22May 26−$0.23−$0.25Aug 26−$0.23−$0.22Nov 26
Latest (Nov 26): Estimate −$0.23, Reported −$0.22.

Recursion Pharmaceuticals' latest quarter

Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did Recursion Pharmaceuticals beat earnings?

Recursion Pharmaceuticals (RXRX) reported on Nov 2, 2026 and beat the EPS estimate: −$0.22 against −$0.23 (+3.9%).

When does RXRX report earnings?

The next date is not set yet.

Does Recursion Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.